Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Roche Diagnostics and Response Biomedical have entered into a partnership that will allow Roche to market the first line of cardiovascular tests for Response Biomedical's new point-of-care platform.
Subscribe to our email newsletter
The platform, the RAMP 200 (rapid analyte measurement platform), is based on RAMP technology that is already used in laboratories worldwide for West Nile Virus, biodefense tests and the recently FDA-cleared RAMP fu A/B test.
The RAMP cardiovascular product line includes troponin-I, CK-MB, myoglobin and NT-proBNP. Roche has exclusive rights to market the cardiovascular line in the US, Canada and other global markets. The RAMP 200 cardiovascular line is expected to be launched in the first quarter of 2009.
Rodney Cotton, senior vice president of point of care division at Roche diagnostics, said: “The RAMP 200 will allow physicians to treat patients faster because it can help reduce the amount of time from when a patient presents with symptoms to when treatment begins.”